TY - JOUR T1 - Review: empirical atypical coverage does not reduce mortality in hospitalised patients with community acquired pneumonia JF - Evidence Based Medicine JO - Evid Based Med SP - 74 LP - 74 DO - 10.1136/ebm.11.3.74 VL - 11 IS - 3 A2 - , Y1 - 2006/06/01 UR - http://ebm.bmj.com/content/11/3/74.abstract N2 - Shefet D, Robenshtok E, Paul M, et al. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005;165:1992–2000.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In hospitalised patients with community acquired pneumonia (CAP), does empirical antibiotic coverage of atypical pathogens reduce mortality and improve clinical efficacy? Clinical impact ratings Internal medicine ★★★★★★☆ Geriatrics ★★★★★☆☆ Infectious disease ★★★★★★☆ Data sources: CENTRAL (Issue 4, 2004), Medline (to August 2004), EMBASE/Excerpta Medica (to July 2003), and reference lists of identified studies. Study selection and assessment: randomised controlled trials (RCTs) that compared an oral or intravenous antibiotic regimen with coverage of atypical pathogens (macrolides, fluoroquinolones, tetracycline, doxycycline, or chloramphenicol) with a regimen without such coverage for treatment of CAP in hospitalised adults. Studies with >30% dropout rate or involving mainly immune suppressed patients were excluded. Studies were assessed for quality of allocation generation and concealment, blinding, and intention to treat analysis. … ER -